Litigation

Recent Posts

GlaxoSmithKline To Settle 3 Federal Investigations For $3 Billion
Posted on 4 Nov 2011 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline plc (GSK) has reached an agreement in principal to settle three United States federal criminal and civil investigations for $3 billion, the company said Nov. 3 in a press release on its Web site. GSK said... Read More

Tags: diabetes drug , Marketing , Medicaid , U.S. attorney for Massachusetts , Litigation , GSK , GlaxoSmithKline , Settlement , Avandia , U.S. Justice Department

Avandia Off Market In Europe; FDA To Restrict Its Use, Orders Probe of GSK Study
Posted on 23 Sep 2010 by Tom Moylan

(Mealey's) The European Medicines Agency (EMA) on Sept. 23 recommended that the marketing authorization for GlaxoSmithKline PLC's (GSK) controversial anti-diabetes drug Avandia be suspended, and the Food and Drug Administration simultaneously... Read More

Tags: diabetes drug , EMA , European Medicines Agency , drugs & devices , Food and Drug Administration , Actos , rosiglitazone , TIDE study , Thiazolidinedione Intervention With Vitamin D Evaluation study , FDA , Litigation , Committee for Medicinal Products for Human Use , GSK , GlaxoSmithKline , pioglitazone , RECORD clinical trial , stroke , Avandia , Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia clinical trial , heart attack

Glaxo To Plead Guilty, Will Pay $3 Billion Stemming From Drug Marketing
Posted on 2 Jul 2012 by Tom Moylan

BOSTON - (Mealey's) GlaxoSmithKline LLC (GSK) agreed June 2 to plead guilty and to pay $3 billion to resolve broad-ranging criminal and civil allegations in Massachusetts federal court regarding the promotion of several prescription drugs, failure... Read More

Tags: diabetes drug , Lotronex , Wellbutrin , drugs , GlaxoSmithKline LLC , False Claims Act , United States ex rel. Greg Thorpe v. GlaxoSmithKline PLC , Imitrex , Valtrex , Paxil , antidepressants , United States of America v. GlaxoSmithKline LLC , U.S. Department of Justice , U.S. Food and Drug Administration , Litigation , GSK , Flovent , prescription drugs , Avandia

No New Trial In Actos MDL Bellwether Case, But Punitives Are Cut From $9 Billion To $36 Million
Posted on 29 Oct 2014 by Tom Moylan

LAFAYETTE, La. — (Mealey’s) Takeda Pharmaceutical Co. Ltd. and Eli Lilly and Co. will not get a new trial in the first Actos bladder cancer multidistrict litigation bellwether case, but a Louisiana federal judge on Oct. 27 reduced the $9 billion... Read More

Tags: diabetes drug , Terrence Allen v. Takeda Pharmaceuticals North America , punitive damages , In Re: Actos [Pioglitazone] Products Liability Litigation , Actos , product liability , Terrence Allen , bladder cancer , MDL Docket No. 2299 , Louisiana , Litigation , multidistrict litigation , Eli Lilly and Co. , verdict , torts , Takeda Pharmaceutical

GSK To Pay $229 Million To Settle Avandia, Drug Lawsuits By 8 State Attorneys General
Posted on 26 Jul 2013 by Tom Moylan

LONDON — (Mealey's) GlaxoSmithKline plc (GSK) on July 24 said it has reached an agreement in principle with the attorneys general of seven states to pay $229 million to resolve lawsuits relating to the development and marketing of the diabetes... Read More

Tags: diabetes drug , U.S. Securities and Exchange Commission , Humana Healthcare , Litigation , GSK , GlaxoSmithKline , Settlement , Avandia

3rd Circuit: Humana Can Sue GSK For Reimbursement For Avandia-Related Expenses
Posted on 29 Jun 2012 by Tom Moylan

PHILADELPHIA - (Mealey's) Medicare Advantage provider Humana Medical Plan Inc. is allowed under Medicare law to seek reimbursement from GlaxoSmithKline PLC (GSK) for the costs of treating insurance customers who were injured by GSK's Avandia diabetes... Read More

Tags: diabetes drug , Third Circuit , Medicare , In Re: Avandia Marketing , Humana Insurance Co. , class action , managed care , Litigation , GSK , GlaxoSmithKline , Medicare Secondary Payer Act , Sales Practices and Products Liability Litigation , Humana Medical Plan , Avandia , Medicare Advantage

$2.36B Glaxo Charge Covers Avandia, Paxil Litigation, Other Legal Costs
Posted on 15 Jul 2010 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and... Read More

Tags: diabetes drug , Mealey’s , drugs , drugs & devices , U.S. Securities and Exchange Commission , personal injury , Paxil , paroxetine , product liability , Apotex , Litigation , GSK , GlaxoSmithKline , lawsuit , Glaxo , antidepressant , torts , Avandia

W.Va. Jury Finds Spoliation Of Evidence, Awards $155,000 Against Actos Manufacturer Takeda
Posted on 18 Nov 2014 by Tom Moylan

MARTINSBURG, W.Va. — (Mealey’s) A West Virginia state court jury on Nov. 17 found that Actos is not unsafe and that manufacturer Takeda Pharmaceutical Co. Ltd. was not negligent in the case of a man who developed bladder cancer while taking... Read More

Tags: diabetes drug , punitive damages , West Virginia , spoliation of evidence , Actos , product liability , compensatory damages , bladder cancer , Richard F. Myers v. Takeda Pharmaceuticals America Inc. , Litigation , Takeda Pharmaceutical Co. Ltd. , verdict , torts

Glaxo Takes $2.36 Billion Charge On Legal Costs
Posted on 15 Jul 2010 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) Pharmaceutical company GlaxoSmithKline said Thursday it expects to take a $2.36 billion charge against second-quarter earnings for the costs of settling court cases over the antidepressant Paxil and diabetes drug Avandia. The company said... Read More

Tags: diabetes drug , European Medicines Agency , birth defects , Paxil , settlements , U.S. Food and Drug Administration , Apotex , Litigation , GSK , GlaxoSmithKline , lawsuit , pharmaceutical , antidepressant , Avandia

Lawsuits Follow Diabetes Drug Actos' Link To Cancer Risk
Posted on 9 Aug 2011 by LexisNexis Litigation Resource Community Staff

TRENTON, N.J. - (AP) The maker of the world's best-selling diabetes drug is facing hundreds of lawsuits and likely a big sales drop as suspicion grows that taking the pill for more than a year raises the risk of bladder cancer. In June, Takeda Pharmaceuticals... Read More

Tags: diabetes drug , lawsuits , European Medicines Agency , Weitz &amp , Food and Drug Administration , Luxenberg , Actos , Januvia , Type 2 diabetes , FDA , bladder cancer , Vioxx , Diabetes Care , Merck , Litigation , diabetes , Avandia

Glaxo Settles Bad Drug Claim For More Than $40 Million
Posted on 24 Jun 2011 by LexisNexis Litigation Resource Community Staff

PROVIDENCE, R.I. - (AP) The American subsidiary of a major British drug maker, GlaxoSmithKline LLC, has agreed to pay more than $40 million to 37 states and Washington, D.C., to settle complaints alleging manufacturing process issues at a now-shuttered... Read More

Tags: diabetes drug , drugs , SB Pharmco , health care , Food and Drug Administration , anti-nausea drug , Paxil , drug maker , Bactroban , Cidra , Medicaid , Avandamet , Litigation , GlaxoSmithKline , antibiotic , antidepressant , Puerto Rico , Kytril